The most recent CFTR modulators combination, elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA), is authorized for the treatment of CF in patients aged 6 years and older with at least one Phe508del CFTR mutation in combination with ivacaftor (IVA). This evidence concerns the gene CFTR and cystic fibrosis.